Aurobindo Pharma is currently trading at Rs. 780.00, up by 5.70 points or 0.74% from its previous closing of Rs. 774.30 on the BSE.
The scrip opened at Rs. 782.00 and has touched a high and low of Rs. 783.50 and Rs. 772.00 respectively. So far shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 830.00 on 04-Dec-2018 and a 52 week low of Rs. 527.05 on 04-Jun-2018.
Last one week high and low of the scrip stood at Rs. 791.75 and Rs. 764.30 respectively. The current market cap of the company is Rs. 45366.83 crore.
The promoters holding in the company stood at 51.87%, while Institutions and Non-Institutions held 34.51% and 13.62% respectively.
Acrotech Biopharma LLC, a wholly owned subsidiary of Aurobindo Pharma USA Inc., USA, which in turn is a wholly owned subsidiary of Aurobindo Pharma, has entered into a definitive agreement to acquire seven marketed oncology injectable products, intellectual property and commercial infrastructure from Spectrum Pharmaceuticals Inc., a US based, global branded oncology company.
The acquisition will provide new opportunities to grow the business by launching innovative branded products in oncology and future synergy with internal development and external products leveraging this commercial infrastructure and support.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
